Daehan Pharmaceutical대한약품

Daehan Pharmaceutical is a small, low-valued drug maker whose profits have slipped from their 2024 peak while the share price has fallen over the past year.

Daehan Pharmaceutical makes basic hospital drugs such as intravenous fluids, ampoules, vials and parenteral nutrition, and sells some over-the-counter products and exports to Southeast Asia. On trailing twelve-month figures to H1 2026 it reported revenue of ₩217B, operating income of ₩30B and net income of ₩28B, with cash of ₩60B and no borrowings listed. The share price closed at ₩25,400 on 2026-10-22, near the lower end of its 52-week range of ₩24,000 to ₩31,650, and is down 14.5% over one year.

What stands out

• Revenue has grown modestly, from ₩171B in 2021 to ₩209B in 2025, with 2025 growth of 2.2%.
• Operating margin has narrowed from 18.6% in 2024 to 13.9% on a trailing basis, and net income has fallen from ₩34B in 2024 to ₩28B trailing.
• Valuation metrics are low: P/E of 5.4, P/B of 0.5 and a dividend yield of 3.9%, with a DCF base fair value of ₩88,739 in the data, well above the current price.
• Free cash flow on a trailing basis is ₩20B and the company holds ₩60B in cash, with liabilities at 16.6% of equity.
• Foreign ownership rose from 19.2% to 20% over about 60 days, while 20-day net flows were small and mixed across foreign, institutional and retail investors.
• Recent filings are mostly insider shareholding reports, plus a half-year report for June 2026 and a 5%+ holding report on 2026-08-06. No news headlines were included in the data.

What to watch

• The next results and the full detail of the half-year report, since the margin decline is the main question in the numbers.
• Further 5%+ holding or insider shareholding filings, which may show changes in major holders.
• Whether the company's margins and profits stabilise, as the data does not include management guidance or forecasts.